Open AccessPerioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial
Author(s) -
Alice C. Wei,
Fang Shu Ou,
Qian Shi,
Xiomara W. Carrero,
Eileen Mary O'Reilly,
Jeffrey A. Meyerhardt,
Robert A. Wolff,
Hedy L. Kindler,
Douglas B. Evans,
Vikram Deshpande,
Joseph Misdraji,
Eric P. Tamm,
Dushyant V. Sahani,
Malcolm J. Moore,
Elliot Newman,
Nipun B. Merchant,
Jordan Berlin,
Laura Williams Goff,
Peter W.T. Pisters,
Mitchell C. Posner
Publication year - 2019
Publication title -
annals of surgical oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-019-07685-1
Subject(s) - medicine , pancreaticoduodenectomy , erlotinib , gemcitabine , surgical oncology , general surgery , adenocarcinoma , oncology , chemotherapy , cancer , pancreas , epidermal growth factor receptor
There is considerable interest in a neoadjuvant approach for resectable pancreatic ductal adenocarcinoma (PDAC). This study evaluated perioperative gemcitabine + erlotinib (G+E) for resectable PDAC.